[HTML][HTML] Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC
T Chu, R Zhong, H Zhong, BO Zhang, W Zhang… - Journal of Thoracic …, 2021 - Elsevier
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination of …
angiogenesis has been well established, evidence supporting the chemo-free combination of …
Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
R Zhong, J Teng, B Han, H Zhong - Cancer immunology, immunotherapy, 2011 - Springer
Background Lung cancer is the leading cause for cancer-related mortality and morbidity,
and the survival of late-stage non-small cell lung cancer (NSCLC) remains poor. We hereby …
and the survival of late-stage non-small cell lung cancer (NSCLC) remains poor. We hereby …
[HTML][HTML] hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527
C Li, J Zhang, X Yang, C Hu, T Chu, R Zhong… - Cell death & …, 2021 - nature.com
The relationship between circular RNA (circRNA) and cancer stem cells (CSCs) is uncertain.
We have investigated the combined influence of CSCs, circRNA (hsa_circ_0003222), and …
We have investigated the combined influence of CSCs, circRNA (hsa_circ_0003222), and …
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
J Lu, H Zhong, T Chu, X Zhang, R Li… - European …, 2019 - Eur Respiratory Soc
Background Anlotinib has been demonstrated in clinical trials to be effective in prolonging
the progression-free survival (PFS) and overall survival (OS) of refractory advanced nonsmall …
the progression-free survival (PFS) and overall survival (OS) of refractory advanced nonsmall …
Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI …
…, H Zhong, B Han, J Xia, R Zhong - … Journal of Cancer, 2023 - Wiley Online Library
Treatments for NSCLC patients with EGFR‐TKI resistance are limited. Given that immunotherapy
and antiangiogenic agents may have synergistic antitumor effects, we aimed to analyze …
and antiangiogenic agents may have synergistic antitumor effects, we aimed to analyze …
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of …
…, R Zhong, W Zhang, T Chu, H Zhong… - … Journal of Cancer, 2020 - Wiley Online Library
This study aimed to compare the differences in characteristics and prognoses between Asian
and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC). We …
and white patients receiving immunotherapy for nonsmall cell lung cancer (NSCLC). We …
RETRACTED ARTICLE: MMP9 activation triggered by epidermal growth factor induced FoxO1 nuclear exclusion in non-small cell lung cancer
J Pei, Y Lou, R Zhong, B Han - Tumor Biology, 2014 - Springer
The molecular mechanism underlying activation of matrix metallopeptidase 9 (MMP9) in non-small
cell lung cancer (NSCLC) cells, which controls cancer invasiveness and metastasis, …
cell lung cancer (NSCLC) cells, which controls cancer invasiveness and metastasis, …
[HTML][HTML] Tumor-infiltrating CD45RO+ memory cells correlate with favorable prognosis in patients with lung adenocarcinoma
Z Hu, X Gu, R Zhong, H Zhong - Journal of thoracic disease, 2018 - ncbi.nlm.nih.gov
Background The present study aimed to investigate the association of CD45RO+, CD8+,
CCR7+ and FOXP3+ tumor-infiltrating lymphocytes (TILs) with the clinicopathological features …
CCR7+ and FOXP3+ tumor-infiltrating lymphocytes (TILs) with the clinicopathological features …
Sonographic features of endobronchial ultrasonography predict intrathoracic lymph node metastasis in lung cancer patients
L Wang, W Wu, Y Hu, J Teng, R Zhong, B Han… - The Annals of thoracic …, 2015 - Elsevier
Background Intrathoracic lymph node sampling by endobronchial ultrasonography-guided
transbronchial needle aspiration (EBUS-TBNA) has become a standard of care in staging …
transbronchial needle aspiration (EBUS-TBNA) has become a standard of care in staging …
Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
…, J Xu, R Qiao, B Han, H Zhong, R Zhong - Cancer Medicine, 2023 - Wiley Online Library
Objectives Treatments for advanced small‐cell lung cancer (SCLC) patients who are resistant
to first‐line chemotherapy are limited. Given that antiangiogenic agents and immune‐…
to first‐line chemotherapy are limited. Given that antiangiogenic agents and immune‐…